John Scholler News Today

A new approach that delivers a "one-two punch" to help T cells attack solid tumors is the focus of a preclinical study by researchers from the Perelman School of Medicine at the University of Pennsylvania.

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.